A Study of Sovilnesib in Subjects with Ovarian Cancer
This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics
(PK), and efficacy of sovilnesib at different dose levels to establish the Recommended
Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer
(HGSOC...
Age: 18 years - 66+
Gender: Female
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk
(Herceptin Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM])
to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients
with HER...
Age: 18 years - 66+
Gender: Female
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back (recurrent) or does not respond to treatment (...
Age: 18 years - 66+
Gender: Female
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This phase II trial studies the effects of the combination of olaparib and durvalumab,
cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients
with endometrial cancer that has come back (recurrent) or does not respond to treatme...
Age: 18 years - 66+
Gender: Female
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with
atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or
primary peritoneal cancer that has come back (recurrent). Chemotherapy drugs, such ...
Age: 18 years - 66+
Gender: Female